Interleukin 31 (IL31) (N-Term) antibody

Details for Product No. ABIN1002634
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Synonyms IL31, IL-31, 1700013B14Rik
Epitope
N-Term
(16), (7), (4), (4), (2), (2), (1), (1), (1)
Reactivity
Mouse (Murine)
(68), (35), (13)
Host
Rabbit
(85), (4)
Clonality
Polyclonal
Conjugate
Un-conjugated
(9), (4), (4), (3), (3), (3), (3), (3), (3), (3), (3), (1), (1), (1)
Application
ELISA, Western Blotting (WB), Immunohistochemistry (IHC)
(57), (40), (30), (20), (13), (9), (3), (3), (1)
Pubmed 4 references available
Quantity 100 μg
Shipping to United States (Change)
Availability Will be delivered in 6 to 7 Business Days
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN1002634
514.01 $
Plus shipping costs $45.00

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen IL-31 antibody was raised against a 16 amino acid peptide from near the amino terminus of mouse IL-31 (Genbank accession No. AAS82846).
Isotype IgG
Purification Affinity chromatography purified via peptide column.
Alternative Name Interleukin 31
Background Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.
Application Notes IL-31 antibody can be used for the detection of IL-31 by Western blot at 2.5 – 5 µg/ml. (Optimal dilution should be determined by user.) Antibody can also be used for immunohistochemistry and ELISA and might be suited for other applications not tested so far.
Restrictions For Research Use only
Format Liquid
Buffer Antibody is supplied in PBS containing 0.02% sodium azide.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Antibody can be stored at 4ºC, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. During shipment, small volumes of antibody will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 myl or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap.
Storage 4 °C
Expiry Date 12 months
Product cited in: Dillon, Sprecher, Hammond et al.: "Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice." in: Nature immunology, Vol. 5, Issue 7, pp. 752-60, 2004 (PubMed).

Dreuw, Radtke, Pflanz et al.: "Characterization of the signaling capacities of the novel gp130-like cytokine receptor." in: The Journal of biological chemistry, Vol. 279, Issue 34, pp. 36112-20, 2004 (PubMed).

Diveu, Lak-Hal, Froger et al.: "Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling." in: European cytokine network, Vol. 15, Issue 4, pp. 291-302, 2005 (PubMed).

Bilsborough, Leung, Maurer et al.: "IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis." in: The Journal of allergy and clinical immunology, Vol. 117, Issue 2, pp. 418-25, 2006 (PubMed).

Validation Images
Did you look for something else?
back to top